Summary
Dr. Reddy's Laboratories has launched NIVORZ, a biosimilar of nivolumab, in India to enhance immune response against various cancers. Approved by the DCGI for twelve indications, this new intravenous therapy aims to provide affordable, high-quality cancer care options for patients.